glp-1 drugs and thyroid Questions: What's Known and What's Not GLP-1RA and thyroid cancer: New
Description
If you're not, this isn't a reason to start one
Insurance plans place GLP-1 drugs into different coverage tiers, often requiring prior authorization or high out-of-pocket costs
Our findings strongly suggest the answer is yes. Primes recent real-world study found 63% of high-potency GLP-1 (Wegovy or Zepbound) users who started treatment in Q1 2024 are still taking their medication after a year
GLP-1 receptor agonists such as semaglutide and tirzepatide support weight loss and blood sugar control by increasing satiety and improving glucose regulation
.png)
without HF: HR 0.44
However, renal effects of GLP-1 in heart failure (HF) has not been elucidated
